MMED vs TNDM
MMED: MiniMed is a diabetes care technology company specializing in automated insulin delivery pumps, continuous glucose monitors, and smart insulin pens for global Type 1 and Type 2 diabetes management. TNDM: Tandem designs intelligent, consumer-friendly insulin pumps with automated closed-loop technology to help people with insulin-dependent diabetes manage their condition with greater flexibility and less burden.
Side-by-side fundamentals
| Metric | MMED | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.33 | $16.91 | |
| Market cap as of 2026-07-23 | $4.6B | $1.2B | |
| Net margin as of 2026-07-23 | -10.7% | -9.2% | TNDM higher |
| Gross margin as of 2026-07-23 | +54.2% | +54.9% | TNDM higher |
| Operating margin as of 2026-07-23 | -6.1% | -8.2% | MMED higher |
| ROE as of 2026-07-23 | -9.2% | -68.3% | MMED higher |
| ROA as of 2026-07-23 | -7.2% | -10.0% | MMED higher |
| Debt / equity as of 2026-07-23 | 0.00 | 4.58 | MMED lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +4.5% | |
| Revenue CAGR (3y) SEC XBRL | +12.1% | +8.2% | MMED higher |
| Beta as of 2026-07-23 | -0.10 | 1.54 | |
| 1-year return as of 2026-07-22 close | -11.7% | +10.5% | TNDM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.